SCHEMBL2400832

SCHEMBL2400832

CCCC(=O)N1CCC2(CC1)CC(C(=O)O)=NO2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.37
OPRM1 P35372 2/20 0.37
OPRL1 P41146 2/20 0.37
L3MBTL1 Q9Y468 3/20 0.33
KMT2A Q03164 2/20 0.33
NAMPT P43490 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
MAPT P10636 3/20 0.33
POLB P06746 2/20 0.33
MEN1 O00255 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
KDM5C P41229 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
KDM2A Q9Y2K7 1/20 0.32
USP2 O75604 1/20 0.32
CHRNB2 P17787 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA4 P43681 1/20 0.32
CHRNB3 Q05901 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2401291 0.91 L3MBTL1 (0.47) GPR119L3MBTL1KMT2AMAPTPOLB
SCHEMBL2584142 0.81 MAPT (0.49) GPR119OPRM1OPRL1KMT2ANAMPT
SCHEMBL2402380 0.81 GPR119 (0.40) GPR119KMT2AMEN1USP2
SCHEMBL4070022 0.81 GPR119 (0.34) GPR119OPRM1KMT2A
SCHEMBL15309169 0.78 GPR119 (0.40) GPR119NAMPTUSP2
SCHEMBL2399298 0.78 RAB9A (0.56) L3MBTL1KMT2ANPC1RAB9AMAPT
SCHEMBL1639199 0.77 GPR119 (0.57) GPR119MAPTUSP2
SCHEMBL2400865 0.76 GAA (0.40) MAPTPOLBTDP1
SCHEMBL2402983 0.76 L3MBTL1 (0.46) L3MBTL1KMT2ARAB9APOLBMEN1
SCHEMBL2400758 0.75 SLC6A7 (0.44) KMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8557796-B2 Substituted 1-oxa-2,8-diaza-spiro [4,5] dec-2-ene derivatives and related treatment methods GRUENENTHAL GMBH (DE) 2013-10-15 US disclosed
US-8048890-B2 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents GRUENENTHAL GMBH (DE) 2011-11-01 US disclosed
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods SULT1E1, DECR1, CYP8B1 GPR119 883/4885OPRM1 1062/4885OPRL1 2733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.